Nov 4, 6:34 AM ET
CVS Health announced its intention to separate into two independent, publicly traded companies in a transaction intended to be tax-free to the company and shareholders. The separation is expected to be completed in the first half of 2028, subject to customary conditions, and the company also announced third quarter 2026 results and raised its full-year 2026 guidance in a separate release.
- Healthcare solutions company (CVS Health) would include Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health; David Joyner would be Chairman and CEO.
- CVS Pharmacy would include about 9,000 CVS pharmacies, mail pharmacy, MinuteClinic and Health100; Prem Shah would be CEO.
- Separation expected to be completed in the first half of 2028, subject to Board approval, effectiveness of a Form 10 registration statement and tax confirmation.
- Company raised full-year 2026 guidance in a separate press release issued the same day; the amount of the raise is not stated in this filing.
Read the filing on SEC.gov ↗
Nov 4, 6:31 AM ET
CVS Health Corporation announced its third quarter 2026 financial results, reporting total revenues of $108.4 billion and a net income of $2.17 billion. Driven by strong performance across its Health Care Benefits and Pharmacy & Consumer Wellness segments, the company raised its full-year 2026 guidance.
- Third quarter total revenues increased 5.4% year-over-year to $108.4 billion.
- GAAP diluted EPS was $1.68 and Adjusted EPS was $2.09 for the third quarter of 2026.
- Full-year 2026 GAAP diluted EPS guidance was raised to at least $6.98, and Adjusted EPS guidance was raised to at least $8.20.
- Year-to-date cash flow from operations reached $15.3 billion as of September 30, 2026.
Read the filing on SEC.gov ↗
Aug 17, 4:19 PM ET
CVS Health appointed Teresa Heitsenrether, Executive Vice President and Chief Data & Analytics Officer at JPMorgan Chase, to its Board of Directors, effective November 18, 2026. Larry Robbins resigned from the Board effective August 13, 2026, and the company said his resignation was not due to any disagreement with the company. The filing reports no financial results, so the change is a board composition update rather than a change to company performance.
- Teresa Heitsenrether joins the Board effective November 18, 2026, and was determined to be independent under NYSE rules.
- Larry Robbins resigned from the Board effective August 13, 2026, after serving since 2024.
- Heitsenrether's director compensation will match other non-employee directors, prorated for her start date.
- CEO David Joyner said Heitsenrether brings experience in data, analytics and technology.
Read the filing on SEC.gov ↗
Aug 5, 6:32 AM ET
CVS Health reported second-quarter 2026 GAAP diluted EPS of $2.31, up from $0.80 a year earlier, and Adjusted EPS of $2.58, up from $1.81. The company raised its full-year 2026 GAAP EPS, Adjusted EPS and cash flow from operations guidance, citing the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the rest of the year due to elevated cost trends and possible macro headwinds.
- Q2 2026 total revenues rose 7.3% to $106.1 billion; the prior-year quarter included $833 million in legacy litigation charges that did not recur
- Full-year 2026 Adjusted EPS guidance raised to $7.90 to $8.10 from $7.30 to $7.50; GAAP diluted EPS guidance raised to $6.84 to $7.04 from $6.24 to $6.44
- Cash flow from operations guidance raised to at least $11.5 billion from at least $9.5 billion; year-to-date operating cash flow was $10.6 billion
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.